AbbVie Bid for Biotech Could Expand with Experimental Drug
AbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Review today’s 30-year mortgage rate chart to compare trends and identify favorable rates across lenders.
23,821 articlesAbbVie is exploring a cash purchase of about $10.9 billion for a biotech developing an experimental eczema drug, a mo...
Bitcoin fans have watched a calm stretch emerge around the $60,000 mark. This article breaks down what that steady vi...
New cost tallies show the true price of the Iran conflict to U.S. taxpayers near $200 billion, far above early Pentag...
The Senate backed a symbolic war-powers resolution in a tight 50-48 vote, signaling bipartisan unease with Trump-era ...
A high-yield ETF draws retiree interest, but Warren Buffett would never chase yields at the expense of long-term grow...
A surprising all-stock deal sent ON Semiconductor lower, wiping out gains from a strong AI data center narrative. Her...
Bridgewater Associates pivots its recruiting to emphasize resilience, drawing on Ray Dalio’s own history as a ‘terrib...
Memory markets have swung on supply timing. This article breaks down what micron's says this when means for pricing p...
NAIOP rebrands as CREDA, broadening its mandate to advocate, educate, and connect developers, owners, and investors a...
Bloom Energy has drawn big investor attention after a dramatic rally. This guide breaks down what the company does, w...
Dram stocks surged on AI-driven demand, yet the rally carries volatility and a stubborn supply gap. This analysis exp...
Tech volatility hits highest levels this week as the Nasdaq 100 experiences bigger swings. The broader market psychol...